Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary Syndromes: A Canadian Hospital Perspective

Author： Balen R.M.

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.16, Iss.5, 1999-11, pp. : 533-542

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in Patients with Acute Coronary Syndrome in Poland: Modelling Study from the Hospital Perspective

By Orlewska E.

PharmacoEconomics, Vol. 21, Iss. 10, 2003-01 ,pp. : 737-748

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in the Secondary Prevention of Acute Coronary Syndrome

By Brosa M.

PharmacoEconomics, Vol. 20, Iss. 14, 2002-01 ,pp. : 979-987

Adis International

Access to resources Recommend Favorite

Dermatan Sulfate versus Unfractionated Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Surgery for Cancer: A Cost-Effectiveness Analysis

By Attanasio E.

PharmacoEconomics, Vol. 19, Iss. 1, 2001-01 ,pp. : 57-68

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of ticagrelor in acute coronary syndromes

By Henriksson Martin Janzon Magnus

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Iss. 1, 2013-02 ,pp. : 9-18

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Bemiparin Sodium versus Unfractionated Heparin and Oral Anticoagulants in the Acute and Long-Term Treatment of Deep Vein Thrombosis

By Gómez-Outes Antonio

PharmacoEconomics, Vol. 24, Iss. 1, 2006-01 ,pp. : 81-92

Adis International

Access to resources Recommend Favorite